Loading...
Despite the wide application of androgen-deprivation therapy (ADT) for prostate cancer in a variety of settings, an understanding of testicular androgen recovery after discontinuation of ADT is lacking. To evaluate the kinetics of testosterone recovery after ADT, investigators assessed 159 prostate cancer patients enrolled in a multicenter, randomized, placebo-controlled study of the role of thalidomide in delaying time to PSA progression (J Urol 2005; 173:1567). This cohort — which had undergone definitive local therapy (either surgery or radiotherapy) and had rising prostate-specific antigen (PSA) levels with no radiographic evidence of metastases — received 2 cycles of treatment. In cycle 1, patients received 6 months of medical testicul…